HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Figures All Versions of this Article: db07-1594v1 57/5/1312    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martinuzzi, E. Articles by Mallone, R. Search for Related Content PubMed PubMed Citation Articles by Martinuzzi, E. Articles by Mallone, R. Related Collections Related Article Social Bookmarking                What's this?

The Frequency and Immunodominance of Islet-specific CD8⁺ T-cell Responses Change after Type 1 Diabetes Diagnosis and Treatment

¹INSERM, U580, Paris, France
²Université Paris Descartes, Faculté de Médecine René Descartes, Paris, France
³Università di Torino, Dipartimento di Medicina Interna, Torino, Italy
⁴INRA, Immuno-Endocrinology Unit, ENVN, Nantes, France
⁵Université de Nantes, Nantes, France
⁶CHU de Nantes, Hôpital Hôtel-Dieu, Clinique d'Endocrinologie, Nantes, France

Objective: Islet-reactive CD8⁺ T-cells play a key role in the pathogenesis of type 1 diabetes (T1D) in the NOD mouse. The predominant T-cell specificities change over time, but whether similar shifts also occur after clinical diagnosis and insulin treatment in T1D patients is unknown.

Research Design And Methods: We took advantage of a recently validated islet-specific CD8⁺ T-cell IFN- enzyme-linked immunospot (ISL8Spot) assay to follow responses against preproinsulin (PPI), GAD, IA-2 and islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) epitopes in 15 HLA-A2⁺ adult T1D patients close to diagnosis and at a second time point 7-16 months after.

Results: CD8⁺ T-cell reactivities were less frequent at follow-up, as 28.6% of responses tested positive at T1D diagnosis vs. 13.2% after a median of 11 months (P=0.003). While GAD and IA-2 autoantibody (aAb) titers were unchanged in 75% of cases, the fraction of patients responding to PPI and/or GAD epitopes by ISL8Spot decreased from 60-67% to 20% (P<0.02). The previously subdominant IA-2_206-214 and IGRP_265-273 peptides were newly targeted, thus becoming the immunodominant epitopes.

Conclusions: Shifts both in frequency and in immunodominance of CD8⁺ T-cell responses occur rapidly, as compared to slower changes in aAb titers. These different kinetics may suggest complementary clinical applications for T cell and aAb measurements.

Correspondence: Roberto.Mallone{at}paris5.inserm.fr

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article:

Islet Autoreactive CD8 T-cells in Type 1 Diabetes: Licensed to Kill?

Bart O. Roep
Diabetes 2008 57: 1156. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				B. O. Roep Islet Autoreactive CD8 T-cells in Type 1 Diabetes: Licensed to Kill? Diabetes, May 1, 2008; 57(5): 1156 - 1156. [Full Text] [PDF]